← Leaderboards
James Inglese
National Center For Advancing Translational Sciences
$0
Attributed
$0
Total exposure
0
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
—
By mechanism
—
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Design”
- Lawrence Corey · Fred Hutchinson Cancer Center$736,542,541
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- David Heimbrook · Leidos Biomedical Research, Inc.$460,267,569
- Jeffrey P Krischer · University Of South Florida$427,700,530
- David R. Weir · University Of Michigan At Ann Arbor$385,316,144
Research focus
DesignSmall Molecule LibrariesScreeningCollaborationsLaboratoriesBaseGenesProteinsPharmaceutical PreparationsAssay DevelopmentTechnologyCellsLibrariesPathway InteractionsResearch And DevelopmentHigh Throughput ScreeningGeneticBiological ModelsEnzymesPhenotypeAffectMutationLeadSmall Molecule
Grant awards (87)
Ligand-dependent structural dynamics assays$806,341
ZIA · FY2025 · TR · contact PI
Anti-folate chemotype protein degraders$671,951
ZIA · FY2025 · TR · contact PI
Novel Molecular Modalities for Pharmacological Probe and Therapeutic Lead Discovery$537,560
ZIA · FY2025 · TR · contact PI
C. elegans as a model organism for human disease$403,170
ZIA · FY2025 · TR · contact PI
Phenotypic Assay Design and Development$134,390
ZIA · FY2025 · TR · contact PI
Target-based Assays and Screening Strategies$134,390
ZIA · FY2025 · TR · contact PI
Target-based Assays and Screening Strategies for Chemical Probe and Therapeutic Lead Discovery$766,601
ZIA · FY2024 · TR · contact PI
Anti-folate chemotype protein degraders$766,601
ZIA · FY2024 · TR · contact PI
Discovery and Design of Novel Molecular Modalities for Chemical Probe and Therapeutic Lead Discovery$511,067
ZIA · FY2024 · TR · contact PI
Phenotypic Assay Design and Development for Rare and Neglected Diseases$255,534
ZIA · FY2024 · TR · contact PI
C. elegans as a model organism for human disease through the application of phenologs$255,534
ZIA · FY2024 · TR · contact PI
Target-based Assays and Screening Strategies for Chemical Probe and Therapeutic Lead Discovery$693,256
ZIA · FY2023 · TR · contact PI
Anti-folate chemotype protein degraders$554,605
ZIA · FY2023 · TR · contact PI
Ipglycermides Novel potent and selective inhibitors of parasitic phosphoglycerate mutase$277,302
ZIA · FY2023 · TR · contact PI
C. elegans as a model organism for human disease through the application of phenologs$277,302
ZIA · FY2023 · TR · contact PI
Phenotypic Assay Design and Development for Rare and Neglected Diseases$277,302
ZIA · FY2023 · TR · contact PI
Alpha-1 antitrypsin (AAT) deficiency$138,653
ZIA · FY2023 · TR · contact PI
Peroxisome biogenesis disorders (PBDs)$138,651
ZIA · FY2023 · TR · contact PI
Juvenile Myositis$138,651
ZIA · FY2023 · TR · contact PI
Assays to evaluate biological pathways in Parkinsons disease$138,651
ZIA · FY2023 · TR · contact PI
Charcot-Marie-Tooth (CMT) Disease$138,651
ZIA · FY2023 · TR · contact PI
Phenotypic Assay Design and Development for Rare and Neglected Diseases$504,630
ZIA · FY2022 · TR · contact PI
Target-based Assays and Screening Strategies for Chemical Probe and Therapeutic Lead Discovery$450,520
ZIA · FY2022 · TR · contact PI
Peroxisome biogenesis disorders (PBDs)$310,310
ZIA · FY2022 · TR · contact PI
Ipglycermides Novel potent and selective inhibitors of parasitic phosphoglycerate mutase$295,660
ZIA · FY2022 · TR · contact PI
Juvenile Myositis$231,400
ZIA · FY2022 · TR · contact PI
Assays to evaluate biological pathways in Parkinsons disease$208,956
ZIA · FY2022 · TR · contact PI
C. elegans as a model organism for human disease through the application of phenologs$151,250
ZIA · FY2022 · TR · contact PI
Charcot-Marie-Tooth (CMT) Disease$69,307
ZIA · FY2022 · TR · contact PI
Alpha-1 antitrypsin (AAT) deficiency$68,065
ZIA · FY2022 · TR · contact PI
Phenotypic Assay Design and Development for Rare and Neglected Diseases$513,391
ZIA · FY2021 · TR · contact PI
Target-based Assays and Screening Strategies for Chemical Probe and Therapeutic Lead Discovery$464,311
ZIA · FY2021 · TR · contact PI
Peroxisome biogenesis disorders (PBDs)$307,585
ZIA · FY2021 · TR · contact PI
Ipglycermides Novel potent and selective inhibitors of parasitic phosphoglycerate mutase$283,914
ZIA · FY2021 · TR · contact PI
Juvenile Myositis$236,728
ZIA · FY2021 · TR · contact PI
Assays to evaluate biological pathways in Parkinsons disease$229,463
ZIA · FY2021 · TR · contact PI
C. elegans as a model organism for human disease through the application of phenologs$164,447
ZIA · FY2021 · TR · contact PI
Charcot-Marie-Tooth (CMT) Disease$66,554
ZIA · FY2021 · TR · contact PI
Alpha-1 antitrypsin (AAT) deficiency$65,361
ZIA · FY2021 · TR · contact PI
Phenotypic Assay Design and Development for Rare and Neglected Diseases$475,656
ZIA · FY2020 · TR · contact PI
Target-based Assays and Screening Strategies for Chemical Probe and Therapeutic Lead Discovery$420,568
ZIA · FY2020 · TR · contact PI
Ipglycermides Novel potent and selective inhibitors of parasitic phosphoglycerate mutase$260,112
ZIA · FY2020 · TR · contact PI
SARS CoV-2 Nsp1 inhibitor$221,059
ZIA · FY2020 · TR · contact PI
Peroxisome biogenesis disorders (PBDs)$210,414
ZIA · FY2020 · TR · contact PI
Assays to evaluate biological pathways in Parkinsons disease$198,469
ZIA · FY2020 · TR · contact PI
Juvenile Myositis$190,569
ZIA · FY2020 · TR · contact PI
Alpha-1 antitrypsin (AAT) deficiency$70,467
ZIA · FY2020 · TR · contact PI
Charcot-Marie-Tooth (CMT) Disease$70,235
ZIA · FY2020 · TR · contact PI
Phenotypic Assay Design and Development for Rare and Neglected Diseases$445,362
ZIA · FY2019 · TR · contact PI
Target-based Assays and Screening Strategies for Chemical Probe and Therapeutic Lead Discovery$413,556
ZIA · FY2019 · TR · contact PI
Ipglycermides Novel potent and selective inhibitors of parasitic phosphoglycerate mutase$248,996
ZIA · FY2019 · TR · contact PI
Peroxisome biogenesis disorders (PBDs)$200,978
ZIA · FY2019 · TR · contact PI
Juvenile Myositis$170,455
ZIA · FY2019 · TR · contact PI
Alpha-1 antitrypsin (AAT) deficiency$65,232
ZIA · FY2019 · TR · contact PI
Charcot-Marie-Tooth (CMT) Disease$63,254
ZIA · FY2019 · TR · contact PI
Target-based Assays and Screening Strategies for Chemical Probe and Therapeutic Lead Discovery$415,903
ZIA · FY2018 · TR · contact PI
Phenotypic Assay Design and Development for Rare and Neglected Diseases$401,338
ZIA · FY2018 · TR · contact PI
Ipglycermides Novel potent and selective inhibitors of parasitic phosphoglycerate mutase$253,445
ZIA · FY2018 · TR · contact PI
Peroxisome biogenesis disorders (PBDs)$208,228
ZIA · FY2018 · TR · contact PI
Juvenile Myositis$186,330
ZIA · FY2018 · TR · contact PI
Charcot-Marie-Tooth (CMT) Disease$79,542
ZIA · FY2018 · TR · contact PI
Pharmacological Modulation of Parkin Expression and Function to Attenuate Mitochondrial Dysfunction$79,348
ZIA · FY2018 · TR · contact PI
Alpha-1 antitrypsin (AAT) deficiency$78,512
ZIA · FY2018 · TR · contact PI
Giant Axonal Neuropathy (GAN)$75,905
ZIA · FY2018 · TR · contact PI
Target-based Assays and Screening Strategies for Chemical Probe and Therapeutic Lead Discovery$366,582
ZIA · FY2017 · TR · contact PI
Phenotypic Assay Design and Development for Rare and Neglected Diseases$336,523
ZIA · FY2017 · TR · contact PI
Ipglycermides Novel potent and selective inhibitors of parasitic phosphoglycerate mutase$186,230
ZIA · FY2017 · TR · contact PI
Peroxisome biogenesis disorders (PBDs)$176,448
ZIA · FY2017 · TR · contact PI
Juvenile Myositis$156,330
ZIA · FY2017 · TR · contact PI
Alpha-1 antitrypsin (AAT) deficiency$76,532
ZIA · FY2017 · TR · contact PI
Charcot-Marie-Tooth (CMT) Disease$76,532
ZIA · FY2017 · TR · contact PI
Pharmacological Modulation of Parkin Expression and Function to Attenuate Mitochondrial Dysfunction$73,026
ZIA · FY2017 · TR · contact PI
Giant Axonal Neuropathy (GAN)$72,056
ZIA · FY2017 · TR · contact PI
Target-based Assays and Screening Strategies for Chemical Probe and Therapeutic Lead Discovery$262,502
ZIA · FY2016 · TR · contact PI
Phenotypic Assay Design and Development for Rare and Neglected Diseases$262,502
ZIA · FY2016 · TR · contact PI
Peroxisome biogenesis disorders (PBDs)$156,131
ZIA · FY2016 · TR · contact PI
Ipglycermides Novel potent and selective inhibitors of parasitic phosphoglycerate mutase$156,131
ZIA · FY2016 · TR · contact PI
Alpha-1 antitrypsin (AAT) deficiency$65,673
ZIA · FY2016 · TR · contact PI
Pharmacological Modulation of Parkin Expression and Function to Attenuate Mitochondrial Dysfunction$62,974
ZIA · FY2016 · TR · contact PI
Giant Axonal Neuropathy (GAN)$62,974
ZIA · FY2016 · TR · contact PI
Charcot-Marie-Tooth (CMT) Disease$62,974
ZIA · FY2016 · TR · contact PI
Phenotypic Assay Design and Development for Rare and Neglected Diseases$130,000
ZIA · FY2015 · TR · contact PI
Target-based Assays and Screening Strategies for Chemical Probe and Therapeutic Lead Discovery$130,000
ZIA · FY2015 · TR · contact PI
Charcot-Marie-Tooth (CMT) Disease$43,363
ZIA · FY2015 · TR · contact PI
Pharmacological Modulation of Parkin Expression and Function to Attenuate Mitochondrial Dysfunction$43,363
ZIA · FY2015 · TR · contact PI
Giant Axonal Neuropathy (GAN)$43,363
ZIA · FY2015 · TR · contact PI
Alpha-1 antitrypsin (AAT) deficiency$43,363
ZIA · FY2015 · TR · contact PI